TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03436719
Drug: Intravenous antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone - 1000 mg intravenously for 30-90 minutes before surgery
Study: NCT00555750
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactive placebo tablet, by mouth nightly 30 minutes before bed, for two months
Study: NCT03206723
Drug: Eyedrop
Normalized name: Autodrop for Eyedrops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroquinolone eyedrops 4x/day
Study: NCT03206723
Drug: Hydrocodone
Normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocone 1-2 tabs 4x/day if needed
Study: NCT03752294
Drug: Placebo - Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the end of a 9-month randomized-control, double-blind treatment all study participants will cross-over to the 12-month open-label phase with a 3-month non-treatment follow-up
Study: NCT02671058
Drug: Hydrocortisone Acetate
Normalized name: Hydrocortisone Acetate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone Acetate Administered as a Suppository with the Sephure® Rectal Suppository Applicator
Study: NCT01299779
Drug: PEG-ELS
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 1L + 500 cc clear liquids at 6 pm night prior~* 1L + 500 cc clear liquids starting 4 hours prior to colonoscopy
Study: NCT01554111
Drug: phosphosoda rectal enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will have an enema inserted into the rectum and the liquid contents of the enema will be squeezed into the rectum. The patient will need to hold in the enema for several minutes then can release it.
Study: NCT02468323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive regular spinal anesthesia
Study: NCT01044433
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT03893617
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single blinded capsule containing no active medication will be administered at the start of the baseline monitoring period of the acute stress study visit.
Study: NCT01173536
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral repeating dose
Study: NCT00156650
Drug: Testosterone Gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone (T) gel 10 g daily for 6 months
Study: NCT04397653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the placebo arm placebo subcutaneous every 2 weeks will be administered for 24 weeks to high cardiovascular risk haemodialized statin intolerant patients with hypercholesterolemia
Study: NCT04231292
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03066089
Drug: Fenfuro
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01979016
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT00266487
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00633022
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (wet granulation formulation) are available as white, film coated, round, convex tablets manufactured using micronised substance to visually match the active GW856553 tablets are also available. Tablets are packed into high-density polyethylene (HDPE) bottles.
Study: NCT03677401
Drug: Placebo Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Tablets
Study: NCT01968031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02130973
Drug: Standard Clinical Practice Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Clinical Practice Regimen
Study: NCT01971411
Drug: Calcium 500mg with 200 IU Vitamin D - 2 tablets daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03235141
Drug: azithromycin eye drops by essex
Approvals — FDA: no, EMA: no, PMDA: no
Description: azithromycin eye drops,2.5ml/25mg,by ZHUHAI ESSEX BIO-PHARMACEUTICAL),
Study: NCT00050934
Drug: oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00271583
Drug: CDB-2914
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00366288
Drug: PAZ-417
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.
Study: NCT02095574
Drug: [14C]ABT-199 (GDC-0199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]ABT-199 will be administered as a single oral administration
Study: NCT00480298
Drug: Administration of oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00371137
Drug: Xyrem®
Approvals — FDA: no, EMA: no, PMDA: no
Description: two doses
Study: NCT00371137
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution
Study: NCT02013791
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of cyclosporine administered as per protocol
Study: NCT00927784
Drug: Cryoprotective media alone
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive intramyocardial injections of cryoprotective media (placebo).
Study: NCT01092559
Drug: Nitric Oxide generated by the GeNO nitrosyl delivery system
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single short-term exposure to inhaled nitric oxide using the GeNO nitrosyl delivery system.
Study: NCT03580694
Drug: REGN4659
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGN4659 will be administered by intravenous (IV) infusion.
Study: NCT00632242
Drug: ARC1779
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min.
Study: NCT00632242
Drug: ARC1779
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min.
Study: NCT00632242
Drug: ARC1779
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial stepwise infusion of 0.46 mg/kg over 30 minutes and subsequent continuous infusion of an additional 2.88 mg/kg given over 24 hours at a rate of 0.002 mg/kg/min.
Study: NCT00632242
Drug: ARC1779
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min to produce a target plasma concentration of 6 mcg/mL.~Continuous infusion of ARC1779 Injection may continue for ≤ 14 days. After initial 24 hours dose may be titrated to achieve a target plasma concentration of 12 mcg/mL as needed, on the basis of clinical and laboratory data, according to the Investigator's judgment.
Study: NCT01458977
Drug: Truvada® (300 mg tenofovir disoproxil fumarato/200 mg emtricitabine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF/FTC 300/200mg daily during 3 months + Placebo during 6 months
Study: NCT01458977
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during 3 months + TDF/FTC 300/200mg daily during 3 months + Placebo during 3 months
Study: NCT00632242
Drug: ARC1779
Approvals — FDA: no, EMA: no, PMDA: no
Description: In one period of the sequence, ARC1779 will be administered to all subjects as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min in combination with a dummy 30-minute infusion of placebo. In another period, subjects will receive a single infusion of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes in combination with a dummy 30-minute stepwise infusion followed by 4-hour continuous infusion of placebo. In the one other period, subjects will receive the combination of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes and ARC1779 given as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min
Study: NCT04258397
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT01932112
Drug: Adenosine arm
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After pulmonary vein isolation,20mg Intracardiac adenosine will be given to treatment group, will evaluate pulmonary vein reconnection.
Study: NCT02387060
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal administration of fentanyl 25 mcg
Study: NCT01115725
Drug: Gonal-f® (follitropin alfa)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonal-f® (follitropin alfa) will be given once daily subcutaneously at a starting dose of 150-375 international unit per day (IU/day) by self-administered injection via a pen device for first 5 days. After Day 5, Gonal-f® dose will be adjusted according to the investigator's discretion until ovarian response observed.
Study: NCT02288923
Drug: Pre-medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive 1g paracetamol pre-operatively. Those on non steroidal anti inflammatory drugs may continue to take them. Apart from these, no other pain relieving pre-medications are to be used. Patients may be given anxiolysis using temazepam 10-20mg or diazepam 2-5mg by mouth if required. Antacid premedication is permitted using ranitidine, metoclopramide or proton pump inhibitors.
Study: NCT02288923
Drug: Post-operative analgesia - ibuprofen and paracetamol
Normalized name: codeine and paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will be given 1g paracetamol 6 hourly and 400mg ibuprofen 8 hourly unless there are contraindications. If patients are on an alternative non-steroidal anti inflammatory drug then this may be substituted for ibuprofen.
Study: NCT02288923
Drug: Regular anti emetics
Normalized name: INVESTIGATIONAL ANTI-NAUSEA AND ANTI-EMETIC DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive 4mg ondansetron regularly for 2 days. They will be prescribed 50mg cyclizine as an addition to this if needed.
Study: NCT01686217
Drug: ASP015K ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral extended release (ER) at three dosing levels
Study: NCT01686217
Drug: ASP015K IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral immediate release (IR)
Study: NCT00095901
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03184649
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: It is a pre-analgesic will be taken before painful procedures.
Study: NCT03790488
Drug: JTX-4014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT00264004
Drug: AZD2171
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg \& 45 mg oral tablet
Study: NCT01861249
Drug: SAR339658
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Solution for infusion~Route of administration: Intravenous
Study: NCT01214629
Drug: LY2523355
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 alone arm is 0.125 milligrams per meter square per day (mg/m²/day).
Study: NCT01214629
Drug: LY2523355
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 + pegfilgrastim is 4 mg/m²/day.
Study: NCT01710358
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT04385043
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive only standard therapy for Covid-19 infection
Study: NCT01880385
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
Study: NCT04391959
Drug: AZR-MD-001 Active
Normalized name: eptacog alfa activated 0.001 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZR-MD-001 is an active ophthalmic ointment
Study: NCT02297230
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (Xeloda®) 750 mg/m2 twice/daily given orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
Study: NCT01880385
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
Study: NCT01712568
Drug: Test Product (Ropinirole)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: one Tablet at 0 hour
Study: NCT04406194
Drug: AVIGAN 200 mg Film Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVIGAN 200 mg FT is containing 200 mg favipiravir manufactured by Toyama, Japan.
Study: NCT04140591
Drug: Proton-pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI: Pariet EC 20mg/QDAC
Study: NCT00214864
Drug: docetaxel, capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: cohort 1 = capecitabine 900mg/m2 BID POx14 days and docetaxel 36mg/m2 day1\&8 cohort 2 = capecitabine 650mg/m2 BID POx14 days and docetaxel 30mg/m2 day1\&8 cohort 3 = capecitabine 850mg/m2 BID POx14 days and docetaxel 30mg/m2 day1\&8
Study: NCT03649750
Drug: Mucinex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucinex® 600 mg ER bi-layer tablets
Study: NCT04391959
Drug: AZR-MD-001 Vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZR-MD-001 is a vehicle ophthalmic ointment
Study: NCT03675893
Drug: LY3023414
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3023414 is a potent selective inhibitor of the class I PI3K isoforms, mTOR, and DNA-PK.
Study: NCT00897104
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to rizatriptan or sumatriptan, single dose placebo tablet taken orally
Study: NCT03105193
Drug: IV Saline bolus and infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of normal saline at induction 3 day postoperative infusion of normal saline administered by ambit pump
Study: NCT03105193
Drug: IP Saline bolus and infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal bolus of normal saline down first port site. 3 day post operative intraperitoneal infusion of normal saline via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
Study: NCT03105193
Drug: IV lignocaine bolus and infusion
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous lignocaine bolus at induction. 3 day postoperative IV infusion of lignocaine administered by ambit pump
Study: NCT03105193
Drug: IP Lignocaine bolus and infusion
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal bolus of lignocaine down first port site. 3 day post operative intraperitoneal infusion of lignocaine via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
Study: NCT03787017
Drug: FDC(MP-513 20mg/Metformin XR 1000mg)
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01097694
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00004906
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004906
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00881569
Drug: CS-7017
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-7017 administered orally, twice daily continuously for 6 weeks
Study: NCT01652638
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered subcutaneously.
Study: NCT02966860
Drug: Oral solution OC/APAP
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01447095
Drug: Prostacyclin 1 ng/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous i.v. infusion of epoprostenol 1 ng/kg/min day 5-10 after SAH
Study: NCT01447095
Drug: Prostacyclin 2 ng/kg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous i.v. infusion of epoprostenol 2 ng/kg/min day 5-10 after SAH
Study: NCT01447095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous i.v. infusion with placebo day 5-10 after SAH
Study: NCT02412423
Drug: post-transplantation cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00269386
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin S/R 1g once daily April 2004 - Clarithromycin S/R (Klaricid XL) ceased to be abailable and subsequent patients will receive standard Clarithromycin 500mg bd
Study: NCT00269386
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03300687
Drug: FX-322
Normalized name: Prevail-FX
Approvals — FDA: no, EMA: no, PMDA: no
Description: intratympanic injection
Study: NCT03300687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intratympanic injection
Study: NCT02979132
Drug: Eisensulfat LOMAPHARM 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral intake of an 'Eisensulfat LOMAPHARM 50 mg' tablet every morning for 90 days
Study: NCT04672928
Drug: IBI318
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg,iv,Q4W
Study: NCT01075945
Drug: artemether- lumefantrine
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: twenty tablet in eight doses
Study: NCT04432857
Drug: AN0025
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT02480114
Drug: Hydrocodone/Acetaminophen
Normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesia
Study: NCT02480114
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal Analgesia
Study: NCT02480114
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NSAID Analgesia
Study: NCT02480114
Drug: Magic Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Solution to treat mucositis
Study: NCT01937559
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02751996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04003441
Drug: DWP14012 tablet A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
Study: NCT04003441
Drug: DWP14012 tablet B
Normalized name: ACTION B-100 TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
Study: NCT03481036
Drug: Direct Acting Antivirals
Normalized name: DIRECT ACTING ANTIVIRALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir and Daclatasvir
Study: NCT03481036
Drug: DAAs in Cirrhotics Genotype 2/3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir and Daclatasvir with weight based ribavirin
Study: NCT03481036
Drug: DAAs in Cirrhotics Genotye 1,4,5,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir and Ledipasvir with weight based ribavirin
Study: NCT00268164
Drug: lactobacilus acidophilus & bifidobacterium animalis/lactis
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03875261
Drug: Cannabinoid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are treated with cannabinoid derivates with a dose between 1 to 12 puffs, each puffs contains 2,7 mg of delta-9-tetrahidrocannabinol and 2,5 mg of cannabidiol.
Study: NCT00176332
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01923818
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04598607
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3, 4 or 5 tablets of placebo will be given orally once on day 1, day 9 and twice a day on day 3\~8.
Study: NCT00634166
Drug: Topical Antimicrobial/Antifungal Medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: 'Topical Antimicrobial/Antifungal Medications' Various topical antimicrobials and antifungals include: Bacitracin; Amphotericin B; Silver Sulfadiazine; Cefazolin; Vancomycin; Nystatin; Fluconazole; Piperacillin Sodium with Tazobactam.
Study: NCT02656121
Drug: Ovulatory Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: only Clomophine Citrate
Study: NCT00219271
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02570854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be dosed with a matching placebo (vehicle control) via up to 30 minutes intravenous infusion.
Study: NCT01740986
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, b.i.d
Study: NCT00819221
Drug: AZD2281
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules, oral, bd, 2 months
Study: NCT00819221
Drug: liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: once every 4 weeks at 40mg/m2
Study: NCT02016560
Drug: florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02423577
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dry powder administered by nasal inhalation